TY - JOUR
T1 - No prominent role for complement C1-esterase inhibitor in Marfan syndrome mice
AU - Hibender, Stijntje
AU - Li, Siyu
AU - Postma, Alex V
AU - Hoogeland, Myrthe E
AU - Klaver, Denise
AU - Pouw, Richard B
AU - Niessen, Hans W
AU - Driessen, Antoine Hg
AU - Koolbergen, David R
AU - de Vries, Carlie Jm
AU - Baars, Marieke Jh
AU - Houweling, Arjan C
AU - Krijnen, Paul A
AU - de Waard, Vivian
PY - 2022
Y1 - 2022
N2 - Marfan syndrome (MFS) is a connective tissue disorder causing aortic aneurysm formation. Currently, only prophylactic aortic surgery and blood pressure lowering drugs are available to reduce the risk for aortic rupture. Upon whole genome sequencing (WGS) of a Marfan family, we identified a complement gene C1R variant (p.Ser152Leu), which associated with the severe aortic patients. Therefore, we assessed the role of complement activation in MFS aortic tissue. Expression of various complement genes and proteins was detected in human and murine MFS aneurysm tissue, which prompted us to study complement inhibition in MFS mice. Treatment of the Fbn1C1041G/+ MFS mice with human plasma-derived C1-esterase inhibitor Cetor® resulted in reduced complement deposition, decreased macrophage influx in the aorta and lower circulating TNFα levels. However, in line with previous anti-inflammatory treatments, complement inhibition did not change aortic dilatation rate in this MFS mouse model. Thus, while complement factors/C3 activation were detected in human/murine MFS aorta, Cetor® had no effect on aortic dilatation in MFS mice, indicating that complement inhibition is not a suitable treatment strategy in MFS.
AB - Marfan syndrome (MFS) is a connective tissue disorder causing aortic aneurysm formation. Currently, only prophylactic aortic surgery and blood pressure lowering drugs are available to reduce the risk for aortic rupture. Upon whole genome sequencing (WGS) of a Marfan family, we identified a complement gene C1R variant (p.Ser152Leu), which associated with the severe aortic patients. Therefore, we assessed the role of complement activation in MFS aortic tissue. Expression of various complement genes and proteins was detected in human and murine MFS aneurysm tissue, which prompted us to study complement inhibition in MFS mice. Treatment of the Fbn1C1041G/+ MFS mice with human plasma-derived C1-esterase inhibitor Cetor® resulted in reduced complement deposition, decreased macrophage influx in the aorta and lower circulating TNFα levels. However, in line with previous anti-inflammatory treatments, complement inhibition did not change aortic dilatation rate in this MFS mouse model. Thus, while complement factors/C3 activation were detected in human/murine MFS aorta, Cetor® had no effect on aortic dilatation in MFS mice, indicating that complement inhibition is not a suitable treatment strategy in MFS.
U2 - https://doi.org/10.1530/VB-22-0016
DO - https://doi.org/10.1530/VB-22-0016
M3 - Article
C2 - 36279189
SN - 2516-5658
VL - 4
SP - 40
EP - 49
JO - Vascular biology (Bristol, England)
JF - Vascular biology (Bristol, England)
IS - 1
ER -